Nat Commun:突破!中山大学蒋先兴团队开发了脂联素的激动剂,对于治疗肝纤维化有重要应用前景

2020-11-21 椰子 iNature

慢性非酒精性脂肪性肝炎(NASH)是一种代谢性疾病,通常会导致肝纤维化,这是一种治疗选择有限的疾病。脂联素是一种脂联细胞因子,通过与其受体AdipoR1和AdipoR2结合来调节葡萄糖和脂质代谢。

慢性非酒精性脂肪性肝炎(NASH)是一种代谢性疾病,通常会导致肝纤维化,这是一种治疗选择有限的疾病。脂联素是一种脂联细胞因子,通过与其受体AdipoR1和AdipoR2结合来调节葡萄糖和脂质代谢,据报道,AdipoRs信号传导可增强脂肪酸氧化和葡萄糖摄取。

中山大学蒋先兴团队在Nature Communications 在线发表题为“AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis”的研究论文,该研究合成并报告了一种基于脂联素的激动剂JT003,它可以有效地改善高脂饮食诱导的NASH小鼠的胰岛素抵抗,并抑制CCl4诱导的肝纤维化中的肝星状细胞(HSC)活化。

机理研究表明,JT003同时刺激AdipoR1和AdipoR2介导的信号通路以及PI3K-Akt通路。此外,JT003治疗显着改善了ER线粒体轴功能,这有助于减少HSC的活化。因此,AdipoR1 / AdipoR2双重激动剂可改善小鼠模型中的NASH和纤维化,这为开发基于AdipoRs的肝纤维化治疗剂提供了药理和生物学基础。

非酒精性脂肪性肝炎(NASH),伴随着不同程度的炎症和纤维化,将发展为肝硬化和肝细胞癌(HCC)等终末期肝病。它也是血管疾病,门静脉高压症,2型糖尿病(T2DM)和严重肾脏疾病的严重危险因素,可能导致不良后果和极高的死亡率。

与炎症小体直接或间接相关的NASH发病机制引起了肝纤维化的发展。肝细胞胰岛素抵抗会增加肝脏中游离脂肪酸(FFA)的吸收和合成,使肝细胞对氧化损伤,内质网应激(ER应激)和线粒体功能障碍敏感,这将激活肝星状细胞(HSC)并导致肝纤维化。现在认为各种收敛途径或因素与NASH相关纤维化有关:氧化应激,炎性体激活,内质网应激和线粒体功能障碍。

针对NASH的病因和发病机制,正在对具有不同靶标的几种药物进行临床试验测试,包括过氧化物酶体增殖物激活受体(PPAR)激动剂,如saroglitazar和pioglitazone,法呢类X受体(FXR)激动剂奥贝胆酸(OCA) 和胰高血糖素样肽-1受体(GLP1R)激动剂及其类似物。但是,已观察到这些候选药物的不良副作用,例如PPAR激动剂的心血管,骨折和膀胱癌风险,FXR激动剂奥贝胆酸(OCA)的严重瘙痒症以及NASH患者的严重胃肠道疾病。迄今为止,尚无批准的用于肝纤维化的药物治疗方法,突显了开发针对该疾病的有效治疗策略的迫切要求。

在过去的二十年中,adiponectin(脂联素)及其受体的发现使人们对代谢性疾病的发展有了深入的了解。作为胰岛素敏化剂,脂联素的主要生理作用是改善胰岛素抵抗。脂联素包含高度保守的补体因子C1q样球状结构域(gAd),其能够结合并激活膜受体AdipoR1和AdipoR2。 AdipoR1和AdipoR2均在肝脏和骨骼肌中大量表达,并且它们在全长蛋白中具有66.7%的序列相似性,在配体结合位点(细胞外环1,ECL1)具有86%的相似性。

与AdipoR1和AdipiR2结合后,脂联素主要通过AMP激活的蛋白激酶(AMPK)和过氧化物酶体增殖物激活的受体α(PPARα)信号通路介导脂肪酸氧化和葡萄糖代谢。除协调葡萄糖和脂质代谢外,AMPK还直接介导线粒体的生物发生和体内平衡,这可以缓解NASH中发生的能量压力。据报道,脂联素/ AdipoR2信号激活肝PPARα可抑制促炎基因的表达。此外,AdipoR1信号可以激活肝细胞PI3K-Akt通路,据报道在调节胰岛素抵抗,细胞增殖和细胞凋亡方面起主要作用。这些发现表明,AdipoRs系统是治疗NASH和相关纤维化的潜在药物靶标。

该研究合成并报告了一种基于脂联素的激动剂JT003,它可以有效地改善高脂饮食诱导的NASH小鼠的胰岛素抵抗,并抑制CCl4诱导的肝纤维化中的肝星状细胞(HSC)活化。机理研究表明,JT003同时刺激AdipoR1和AdipoR2介导的信号通路以及PI3K-Akt通路。此外,JT003治疗显着改善了ER线粒体轴功能,这有助于减少HSC的活化。因此,AdipoR1 / AdipoR2双重激动剂可改善小鼠模型中的NASH和纤维化,这为开发基于AdipoRs的肝纤维化治疗剂提供了药理和生物学基础。

原始出处:

Hongjiao Xu, Qian Zhao, Nazi Song, et al.AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis.Nat Commun. 2020 Nov 16;11(1):5807. doi: 10.1038/s41467-020-19668-y.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1943073, encodeId=dcc719430e3b7, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Feb 03 12:43:59 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884802, encodeId=d80f18848026d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 13:43:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808258, encodeId=b120180825861, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Aug 04 06:43:59 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921363, encodeId=f5ee9213630e, content=太棒了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56865457282, createdName=ms5000000011976114, createdTime=Sat Jan 30 14:10:55 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087826, encodeId=1bb4208e8269d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Sep 19 05:43:59 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901861, encodeId=5d9f90186127, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:18:32 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555779, encodeId=3fd51555e7908, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901048, encodeId=1aa0901048f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201121/8f3dc6ea81df4279b5102b24dbebf744/33ab977e11c84c8ba0f11a466f555c0c.jpg, createdBy=99d32216909, createdName=120ebf23m47暂无昵称, createdTime=Sat Nov 21 20:40:03 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901047, encodeId=358390104e5e, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a995437180, createdName=ms7000000755366166, createdTime=Sat Nov 21 20:34:08 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1943073, encodeId=dcc719430e3b7, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Feb 03 12:43:59 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884802, encodeId=d80f18848026d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 13:43:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808258, encodeId=b120180825861, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Aug 04 06:43:59 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921363, encodeId=f5ee9213630e, content=太棒了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56865457282, createdName=ms5000000011976114, createdTime=Sat Jan 30 14:10:55 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087826, encodeId=1bb4208e8269d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Sep 19 05:43:59 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901861, encodeId=5d9f90186127, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:18:32 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555779, encodeId=3fd51555e7908, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901048, encodeId=1aa0901048f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201121/8f3dc6ea81df4279b5102b24dbebf744/33ab977e11c84c8ba0f11a466f555c0c.jpg, createdBy=99d32216909, createdName=120ebf23m47暂无昵称, createdTime=Sat Nov 21 20:40:03 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901047, encodeId=358390104e5e, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a995437180, createdName=ms7000000755366166, createdTime=Sat Nov 21 20:34:08 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
    2021-03-09 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1943073, encodeId=dcc719430e3b7, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Feb 03 12:43:59 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884802, encodeId=d80f18848026d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 13:43:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808258, encodeId=b120180825861, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Aug 04 06:43:59 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921363, encodeId=f5ee9213630e, content=太棒了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56865457282, createdName=ms5000000011976114, createdTime=Sat Jan 30 14:10:55 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087826, encodeId=1bb4208e8269d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Sep 19 05:43:59 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901861, encodeId=5d9f90186127, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:18:32 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555779, encodeId=3fd51555e7908, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901048, encodeId=1aa0901048f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201121/8f3dc6ea81df4279b5102b24dbebf744/33ab977e11c84c8ba0f11a466f555c0c.jpg, createdBy=99d32216909, createdName=120ebf23m47暂无昵称, createdTime=Sat Nov 21 20:40:03 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901047, encodeId=358390104e5e, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a995437180, createdName=ms7000000755366166, createdTime=Sat Nov 21 20:34:08 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1943073, encodeId=dcc719430e3b7, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Feb 03 12:43:59 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884802, encodeId=d80f18848026d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 13:43:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808258, encodeId=b120180825861, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Aug 04 06:43:59 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921363, encodeId=f5ee9213630e, content=太棒了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56865457282, createdName=ms5000000011976114, createdTime=Sat Jan 30 14:10:55 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087826, encodeId=1bb4208e8269d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Sep 19 05:43:59 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901861, encodeId=5d9f90186127, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:18:32 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555779, encodeId=3fd51555e7908, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901048, encodeId=1aa0901048f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201121/8f3dc6ea81df4279b5102b24dbebf744/33ab977e11c84c8ba0f11a466f555c0c.jpg, createdBy=99d32216909, createdName=120ebf23m47暂无昵称, createdTime=Sat Nov 21 20:40:03 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901047, encodeId=358390104e5e, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a995437180, createdName=ms7000000755366166, createdTime=Sat Nov 21 20:34:08 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
    2021-01-30 ms5000000011976114

    太棒了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1943073, encodeId=dcc719430e3b7, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Feb 03 12:43:59 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884802, encodeId=d80f18848026d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 13:43:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808258, encodeId=b120180825861, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Aug 04 06:43:59 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921363, encodeId=f5ee9213630e, content=太棒了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56865457282, createdName=ms5000000011976114, createdTime=Sat Jan 30 14:10:55 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087826, encodeId=1bb4208e8269d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Sep 19 05:43:59 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901861, encodeId=5d9f90186127, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:18:32 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555779, encodeId=3fd51555e7908, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901048, encodeId=1aa0901048f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201121/8f3dc6ea81df4279b5102b24dbebf744/33ab977e11c84c8ba0f11a466f555c0c.jpg, createdBy=99d32216909, createdName=120ebf23m47暂无昵称, createdTime=Sat Nov 21 20:40:03 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901047, encodeId=358390104e5e, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a995437180, createdName=ms7000000755366166, createdTime=Sat Nov 21 20:34:08 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1943073, encodeId=dcc719430e3b7, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Feb 03 12:43:59 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884802, encodeId=d80f18848026d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 13:43:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808258, encodeId=b120180825861, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Aug 04 06:43:59 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921363, encodeId=f5ee9213630e, content=太棒了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56865457282, createdName=ms5000000011976114, createdTime=Sat Jan 30 14:10:55 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087826, encodeId=1bb4208e8269d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Sep 19 05:43:59 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901861, encodeId=5d9f90186127, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:18:32 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555779, encodeId=3fd51555e7908, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901048, encodeId=1aa0901048f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201121/8f3dc6ea81df4279b5102b24dbebf744/33ab977e11c84c8ba0f11a466f555c0c.jpg, createdBy=99d32216909, createdName=120ebf23m47暂无昵称, createdTime=Sat Nov 21 20:40:03 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901047, encodeId=358390104e5e, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a995437180, createdName=ms7000000755366166, createdTime=Sat Nov 21 20:34:08 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
    2020-11-24 ms3000001712621089

    good

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1943073, encodeId=dcc719430e3b7, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Feb 03 12:43:59 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884802, encodeId=d80f18848026d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 13:43:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808258, encodeId=b120180825861, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Aug 04 06:43:59 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921363, encodeId=f5ee9213630e, content=太棒了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56865457282, createdName=ms5000000011976114, createdTime=Sat Jan 30 14:10:55 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087826, encodeId=1bb4208e8269d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Sep 19 05:43:59 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901861, encodeId=5d9f90186127, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:18:32 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555779, encodeId=3fd51555e7908, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901048, encodeId=1aa0901048f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201121/8f3dc6ea81df4279b5102b24dbebf744/33ab977e11c84c8ba0f11a466f555c0c.jpg, createdBy=99d32216909, createdName=120ebf23m47暂无昵称, createdTime=Sat Nov 21 20:40:03 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901047, encodeId=358390104e5e, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a995437180, createdName=ms7000000755366166, createdTime=Sat Nov 21 20:34:08 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1943073, encodeId=dcc719430e3b7, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Feb 03 12:43:59 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884802, encodeId=d80f18848026d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 13:43:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808258, encodeId=b120180825861, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Aug 04 06:43:59 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921363, encodeId=f5ee9213630e, content=太棒了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56865457282, createdName=ms5000000011976114, createdTime=Sat Jan 30 14:10:55 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087826, encodeId=1bb4208e8269d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Sep 19 05:43:59 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901861, encodeId=5d9f90186127, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:18:32 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555779, encodeId=3fd51555e7908, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901048, encodeId=1aa0901048f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201121/8f3dc6ea81df4279b5102b24dbebf744/33ab977e11c84c8ba0f11a466f555c0c.jpg, createdBy=99d32216909, createdName=120ebf23m47暂无昵称, createdTime=Sat Nov 21 20:40:03 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901047, encodeId=358390104e5e, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a995437180, createdName=ms7000000755366166, createdTime=Sat Nov 21 20:34:08 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1943073, encodeId=dcc719430e3b7, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Feb 03 12:43:59 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884802, encodeId=d80f18848026d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 13:43:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808258, encodeId=b120180825861, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Aug 04 06:43:59 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921363, encodeId=f5ee9213630e, content=太棒了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56865457282, createdName=ms5000000011976114, createdTime=Sat Jan 30 14:10:55 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087826, encodeId=1bb4208e8269d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Sep 19 05:43:59 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901861, encodeId=5d9f90186127, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:18:32 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555779, encodeId=3fd51555e7908, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901048, encodeId=1aa0901048f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201121/8f3dc6ea81df4279b5102b24dbebf744/33ab977e11c84c8ba0f11a466f555c0c.jpg, createdBy=99d32216909, createdName=120ebf23m47暂无昵称, createdTime=Sat Nov 21 20:40:03 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901047, encodeId=358390104e5e, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a995437180, createdName=ms7000000755366166, createdTime=Sat Nov 21 20:34:08 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
    2020-11-21 120ebf23m47暂无昵称

    学习了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1943073, encodeId=dcc719430e3b7, content=<a href='/topic/show?id=f5bd4931673' target=_blank style='color:#2F92EE;'>#应用前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49316, encryptionId=f5bd4931673, topicName=应用前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af60254, createdName=mhm289, createdTime=Wed Feb 03 12:43:59 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884802, encodeId=d80f18848026d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 09 13:43:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808258, encodeId=b120180825861, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Aug 04 06:43:59 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921363, encodeId=f5ee9213630e, content=太棒了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56865457282, createdName=ms5000000011976114, createdTime=Sat Jan 30 14:10:55 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087826, encodeId=1bb4208e8269d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Sep 19 05:43:59 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901861, encodeId=5d9f90186127, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66365438100, createdName=ms3000001712621089, createdTime=Tue Nov 24 18:18:32 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555779, encodeId=3fd51555e7908, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Nov 23 03:43:59 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901048, encodeId=1aa0901048f3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201121/8f3dc6ea81df4279b5102b24dbebf744/33ab977e11c84c8ba0f11a466f555c0c.jpg, createdBy=99d32216909, createdName=120ebf23m47暂无昵称, createdTime=Sat Nov 21 20:40:03 CST 2020, time=2020-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901047, encodeId=358390104e5e, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a995437180, createdName=ms7000000755366166, createdTime=Sat Nov 21 20:34:08 CST 2020, time=2020-11-21, status=1, ipAttribution=)]
    2020-11-21 ms7000000755366166

    很不错

    0

相关资讯

JCEM:脂联素能预测成人高密度脂蛋白胆固醇外流能力?

众所周知肥胖与低血脂联素、血脂异常和冠状血管疾病(CVD)风险增加有关,然而联系这些条件的机制还尤未可知。胆固醇流出能力(CEC)是高密度脂蛋白(HDL)的一个重要特性,能很好地预测CVD的发生率。

Clin Exp Rheumatol:托珠单抗可以调节类风湿性关节炎患者的血清脂联素和趋化素水平

TCZ能够调节RA患者的血清趋化素和脂联素水平,并与疾病治疗反应无关,这有助于解释TCZ的CV安全性。

JCEM:糖皮质激素替代治疗影响继发性肾上腺皮质功能不全患者血清脂联素和HDL-C水平

由此可见,糖皮质激素替代疗法增加了SAI患者血清脂联素、脂肪来源的抗动脉粥样硬化因子和HDL-C水平。

JCEM:较高的脂联素水平可预测2型糖尿病患者癌症发病率

由此可见,较高的血清脂联素浓度与2型糖尿病患者发生癌症和癌症相关死亡之间独立相关,表明除了心血管疾病和肾脏疾病中存在脂联素悖论外,还可以在另一种糖尿病并发症中观察到。

Diabetes Care:ACS和2型糖尿病患者脂联素、FFA与心血管结局!

与之前的冠心病发生观察性数据相反,脂联素与ACS和2型糖尿病患者的MACE和死亡有关,并从基线增加的脂联素水平与死亡直接相关。与现有的数据一致,FFA与不良预后直接相关。

Metabolism:低水平总的和高分子量脂联素可能预测成年人非酒精性脂肪肝

由此可见,总的和HMW脂联素水平低可能预示着NAFL发展,而与包括肥胖和胰岛素抵抗在内的病理生理因素无关。这种可预测性在女性中很明显。瘦素是体重增加受试者NAFL的重要预测因子。